England - London • Industry focus
2

Life sciences and healthcare

logo

Osborne Clarke LLP

Plus d’information
A range of multinational biopharmaceutical and medical device companies turn to Osborne Clarke LLP for assistance with work such as multi-jurisdictional patent litigation, life sciences M&A and financing transactions. A foursome of partners oversee the team: Will James‘ contentious IP expertise has seen him litigate before the UK courts and the UPC. Matthew Edwards is praised for his ’smooth and successful’ handling of transactions. His corporate expertise is relied upon by the likes of BioNtech. Marcus Vass is well-versed in the digital health sector, and Richard Wilkinson heads up the firm’s healthcare subsector. Tim Harris is a further key contact and extends the unit’s international IP litigation strength.
L’éditorial du Legal 500
Profil
osborneclarke.com
Réseaux sociaux

Témoignages

Collectés indépendamment par l'équipe de recherche du Legal 500.

  • ‘We use Osborne Clarke LLP principally for mid-market M&A support. It's their sweet spot and the team delivers. Clear communication, understanding of our business and what is important to us (acceptable vs unacceptable risks), responsive, deliver under pressure, collaborative and most importantly nice to work with. ’

  • ‘Matthew Edwards is a delight to work with, understands our business and helps deliver transactions in a smooth and successful manner.'

  • 'Laurence Nelson is a rising star of the OC corporate team. ’

  • ‘Will James, Trevor Crosse and their life science IP team are a strong team with broad expertise. They rate very highly for their innovative and excellent solutions and ability to win cases and maximize opportunities. ’

  • ‘Will James is a first-rate litigator, able to see the big picture and bring innovative solutions to the matters he manages. He can get the best out of people and teams, and his personable manner makes him a pleasure to work with.'

  • 'Trevor Crosse has a real depth of knowledge across IP and regulatory life sciences. He is responsive, detail-oriented and thorough. I trust Trevor to get into the weeds on any issue and root out the key issues then provide pragmatic and actionable advice.'

Clients clés

  • Santen
  • BioNTech
  • Amgen
  • Basecamp Research
  • King's College London
  • AviadoBio
  • NeRRe Therapeutics
  • Koa Health
  • Uniphar
  • Albion Capital/UCL Technology Fund

Points forts

  • Advised multinational biotechnology company BioNtech SE on its acquisition of AI start-up Insta Deep in a US$562 million deal.
  • Advising Santen in relation to its leading ophthalmic products for the treatment of glaucoma and high intra-ocular pressure.
  • Advised OMERS on the acquisition of a portion of Enanta Pharmaceuticals' royalty entitlement relating to the antiviral medication Maviret (glecaprevir).

Avocats

Responsable de la pratique

Will James; Matthew Edwards; Marcus Vass; Richard Wilkinson

Autres avocats clés

Trevor Crosse; Laurence Nelson; Tim Harris